15% upside! Why Macquarie is keeping the faith in CSL shares

Would it be a mistake to give up on Australia's iconic healthcare giant now? Macquarie believes so.

| More on:
Confident male executive dressed in a dark blue suit leans against a doorway with his arms crossed in the corporate office

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price took a hit last week after announcing weaker forward earnings estimates
  • Macquarie has reiterated its outperform rating on CSL with a $326 price target
  • The company's defensive nature could prove worthwhile come August earnings season

The defensive sanctity of CSL Limited (ASX: CSL) shares was rocked last week when the biotech giant delivered a disappointing trading update. Shares went for an abrupt 8% trip to the downside in reaction to the news.

Despite lower forward earnings estimates, analysts at Macquarie remain confident in the company's future prospects. As a matter of fact, Macquarie Research has cautioned investors who are considering abandoning CSL in lieu of a better investment.

It could be worse elsewhere

Seldom does Australia's healthcare icon dish out a dissatisfying update. Pointing to higher-than-expected foreign currency headwinds for FY23 and margin pressures from stubbornly high donor fees in FY24, CSL's net profit forecasts fell flat.

Nonetheless, Macquarie analysts have not been dissuaded from their optimistic view on CSL shares. The investment bank has reiterated its outperform rating and $326 price target, acknowledging gross margin pressure in the short term for CSL's plasma segment, Behring, stating:

While we have moderated near-term gross margins for CSL Behring, outer-year forecasts remain largely unchanged with upside from pipeline contributions and improved Ig [immunoglobulin] yields.

With an [earnings per share] EPS compound annual growth rate of 14 per cent per annum over FY22-26, we continue to see the growth outlook as attractive for CSL.

Indeed, Macquarie is trying to focus on the forest and not the trees, counting on the long term remaining strong.

In addition, the team cautions the less defensive pockets of the share market could fare far worse. Expecting more downgrades to filter through, Macquarie sees peak pain in cyclical names in the August earnings season.

What are others saying about CSL shares?

Conducting a post-mortem on CSL after its update, analysts at Citi are mostly sitting in the positive camp as well. Albeit, they opted to prune their price target back to $340 — still hovering above Macquarie's target.

The lofty Citi target would suggest a further 19% upside compared to Macquarie's 15%. Either way, both would be a positive outcome for shareholders.

Created with Highcharts 11.4.3CSL + S&P/ASX 200 Price Return (AUD) PriceZoom1M3M6MYTD1Y5Y10YALL20 Jun 202220 Jun 2023Zoom ▾Jul '22Sep '22Nov '22Jan '23Mar '23May '230www.fool.com.au

For context, CSL shares have failed to outperform the S&P/ASX 200 Index (ASX: XJO) in the last year. With a gain of 7.9%, the biotech is trailing the Aussie benchmark by 6.5% before dividends.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »